ACR on Air cover image

38. Revisiting the Great Debate JAKs vs TNFs

ACR on Air

00:00

The FDA's Statement on JAC Inhibitors

The STAR-RA trial, which was 102,000 patients from the Medicare and Optum and one other database. And even when they matched the patient population to the oral surveillance inclusion exclusion criteria, they still did not come up with statistical non-inferiority for MACEs or malignancies comparing TOFA to TNF inhibitors. So that's a real world study, and that's a large number of patients. Although you can't rule out the possibility, it's certainly not looking at the population that's at high risk. These are generally younger patients, and most of them don't share all the risk factors.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app